Abstract
Microsurgical resection remains the mainstay of treatment for truly benign brain tumors that can be safely resected because of the potential for permanent cure with most histologic findings, including most of the histologic findings discussed in this article. Physicians must keep in mind the indolent nature of many of the benign brain tumors and realize that many patients are likely to live out normal life spans if tumor control is achieved. Therefore, it is not sufficient simply to consider local tumor control rates and short-term toxicity risks when choosing between surgery, stereotactic radiosurgery, and fractionated radiotherapy. Patients need to be apprised of all therapeutic options and to make their decisions with all information required to evaluate the risks and benefits. For benign brain tumors, these decisions may have consequences that last for decades.
MeSH terms
-
Astrocytoma / diagnosis
-
Astrocytoma / radiotherapy
-
Astrocytoma / surgery
-
Brain Neoplasms / diagnosis
-
Brain Neoplasms / radiotherapy*
-
Brain Neoplasms / surgery*
-
Chordoma / diagnosis
-
Chordoma / radiotherapy
-
Chordoma / surgery
-
Dose Fractionation, Radiation
-
Glomus Tumor / diagnosis
-
Glomus Tumor / radiotherapy
-
Glomus Tumor / surgery
-
Humans
-
Magnetic Resonance Imaging
-
Neurocytoma / diagnosis
-
Neurocytoma / radiotherapy
-
Neurocytoma / surgery
-
Paraganglioma / diagnosis
-
Paraganglioma / radiotherapy
-
Paraganglioma / surgery
-
Paraganglioma, Extra-Adrenal / diagnosis
-
Paraganglioma, Extra-Adrenal / radiotherapy
-
Paraganglioma, Extra-Adrenal / surgery
-
Patient Selection*
-
Pinealoma / diagnosis
-
Pinealoma / radiotherapy
-
Pinealoma / surgery
-
Radiosurgery / methods
-
Skull Base Neoplasms / diagnosis
-
Skull Base Neoplasms / radiotherapy
-
Skull Base Neoplasms / surgery
-
Tomography, X-Ray Computed